Troxacitabine in acute leukemia

Ronan T Swords, F. Giles

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Troxacitabine (Troxatyl; BCH-4556; (-)-2′-deoxy-3′- oxacytadine) is the first synthetic L-nucleoside enantiomer to demonstrate broad spectrum cytotoxic activity. It was obtained by exchanging the sulphur endocyclic atom with oxygen in the structure of lamivudine, following the discovery that this agent had cytotoxic, as well as anti-viral activity. The unique "unnatural" stereochemistry of troxacitabine has produced impressive cytotoxic potency against a wide range of malignancies in the laboratory which led to its selection for clinical development. The initial trials with troxacitabine have established its efficacy in both solid and haematological malignancies, including those resistant to ara-C (cytarabine). This review will consider troxacitabine in terms of its pharmacology, mode of action, pharmacokinetics, tolerability and clinical efficacy.

Original languageEnglish
Pages (from-to)219-227
Number of pages9
JournalHematology
Volume12
Issue number3
DOIs
StatePublished - Jun 1 2007
Externally publishedYes

Fingerprint

Leukemia
Cytarabine
Lamivudine
Cytotoxins
Hematologic Neoplasms
Nucleosides
Sulfur
troxacitabine
Pharmacokinetics
Pharmacology
Oxygen
Neoplasms

Keywords

  • Acute myeloid leukaemia
  • Nucleoside analogues
  • Review
  • Troxacitabine

ASJC Scopus subject areas

  • Hematology

Cite this

Swords, R. T., & Giles, F. (2007). Troxacitabine in acute leukemia. Hematology, 12(3), 219-227. https://doi.org/10.1080/10245330701406881

Troxacitabine in acute leukemia. / Swords, Ronan T; Giles, F.

In: Hematology, Vol. 12, No. 3, 01.06.2007, p. 219-227.

Research output: Contribution to journalArticle

Swords, RT & Giles, F 2007, 'Troxacitabine in acute leukemia', Hematology, vol. 12, no. 3, pp. 219-227. https://doi.org/10.1080/10245330701406881
Swords, Ronan T ; Giles, F. / Troxacitabine in acute leukemia. In: Hematology. 2007 ; Vol. 12, No. 3. pp. 219-227.
@article{b9c8fa33e95c4e70ab275265f06b95bc,
title = "Troxacitabine in acute leukemia",
abstract = "Troxacitabine (Troxatyl; BCH-4556; (-)-2′-deoxy-3′- oxacytadine) is the first synthetic L-nucleoside enantiomer to demonstrate broad spectrum cytotoxic activity. It was obtained by exchanging the sulphur endocyclic atom with oxygen in the structure of lamivudine, following the discovery that this agent had cytotoxic, as well as anti-viral activity. The unique {"}unnatural{"} stereochemistry of troxacitabine has produced impressive cytotoxic potency against a wide range of malignancies in the laboratory which led to its selection for clinical development. The initial trials with troxacitabine have established its efficacy in both solid and haematological malignancies, including those resistant to ara-C (cytarabine). This review will consider troxacitabine in terms of its pharmacology, mode of action, pharmacokinetics, tolerability and clinical efficacy.",
keywords = "Acute myeloid leukaemia, Nucleoside analogues, Review, Troxacitabine",
author = "Swords, {Ronan T} and F. Giles",
year = "2007",
month = "6",
day = "1",
doi = "10.1080/10245330701406881",
language = "English",
volume = "12",
pages = "219--227",
journal = "Hematology",
issn = "1024-5332",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Troxacitabine in acute leukemia

AU - Swords, Ronan T

AU - Giles, F.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Troxacitabine (Troxatyl; BCH-4556; (-)-2′-deoxy-3′- oxacytadine) is the first synthetic L-nucleoside enantiomer to demonstrate broad spectrum cytotoxic activity. It was obtained by exchanging the sulphur endocyclic atom with oxygen in the structure of lamivudine, following the discovery that this agent had cytotoxic, as well as anti-viral activity. The unique "unnatural" stereochemistry of troxacitabine has produced impressive cytotoxic potency against a wide range of malignancies in the laboratory which led to its selection for clinical development. The initial trials with troxacitabine have established its efficacy in both solid and haematological malignancies, including those resistant to ara-C (cytarabine). This review will consider troxacitabine in terms of its pharmacology, mode of action, pharmacokinetics, tolerability and clinical efficacy.

AB - Troxacitabine (Troxatyl; BCH-4556; (-)-2′-deoxy-3′- oxacytadine) is the first synthetic L-nucleoside enantiomer to demonstrate broad spectrum cytotoxic activity. It was obtained by exchanging the sulphur endocyclic atom with oxygen in the structure of lamivudine, following the discovery that this agent had cytotoxic, as well as anti-viral activity. The unique "unnatural" stereochemistry of troxacitabine has produced impressive cytotoxic potency against a wide range of malignancies in the laboratory which led to its selection for clinical development. The initial trials with troxacitabine have established its efficacy in both solid and haematological malignancies, including those resistant to ara-C (cytarabine). This review will consider troxacitabine in terms of its pharmacology, mode of action, pharmacokinetics, tolerability and clinical efficacy.

KW - Acute myeloid leukaemia

KW - Nucleoside analogues

KW - Review

KW - Troxacitabine

UR - http://www.scopus.com/inward/record.url?scp=34250633985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250633985&partnerID=8YFLogxK

U2 - 10.1080/10245330701406881

DO - 10.1080/10245330701406881

M3 - Article

C2 - 17558697

AN - SCOPUS:34250633985

VL - 12

SP - 219

EP - 227

JO - Hematology

JF - Hematology

SN - 1024-5332

IS - 3

ER -